Abiopharma

🔍 STIGALL L. JEREMY (Executive)

Company: ClearPoint Neuro, Inc. (CLPT)

Report Date: 2026-03-06

Detailed Transactions and Holdings:

• Acquired 17,778 shares of Common Stock (Direct)
  Date: 2026-03-06 | Code: M | equity_swap_involved: false | shares_owned_after: 94,484.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 6,913 shares of Common Stock at $10.0 per share (Direct)
  Date: 2026-03-06 | Code: F | equity_swap_involved: false | shares_owned_after: 87,571.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 17,778 shares of Restricted Stock Units (Derivative)
  Date: 2026-03-06 | Code: M | equity_swap_involved: false | transaction_form_type: 4 | Footnotes: F1, F1, F1, F1

Footnotes:

• F1: Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.
• F2: Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock.